Health Trials

Gemcitabine

3

Review clinical trials related to Gemcitabine. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Prospective Observational Study of Outcomes After Gemcitabine, Docetaxel, Melphalan, and Carboplatin With Autologous Stem Cell Transplantation in Pediatric Relapsed/Refractory Germ Cell Tumors

To collect information about treatment outcomes in pediatric and adolescent patients with relapsed/refractory germ cells tumors who receive GemDMC with an ASCT.

Participants needed: 30
Trial details
Age: 21+Biological sex: AllType: ObservationalSponsor: M.D. Anderson Cancer CenterUpdated: Jun 23, 2026Locations: 1
Eligibility criteria

Male or female participants, greater than 1 month of age up to 21 years old. Neo... [+2]

Participants who do not or did not receive GemDMC as part of the conditioning re...

Read more
Status: Recruiting

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

The Phase IIIb NIAGARA-2 study aims to expand on the data from the Phase III NIAGARA study by investigating perioperative durvalumab in combination with investigator-selected cisplatin-based neoadjuvant chemotherapy (either ddMVAC or gemcitabine/cisplatin) in a clinical practice setting.

Participants needed: 150
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: AstraZenecaUpdated: Jun 11, 2026Locations: 59
Eligibility criteria

Participants with clinical tumour stage T2-T4aN0/1M0 or T1N1M0 with transitional... [+4]

Evidence of lymph node (N2-N3) or metastatic (M1) disease [+5]

Read more
Status: Recruiting

Evaluation of Concomitant Chemo-radiotherapy With Cisplatine vs Gemcitabin in Locally Advanced Cervicouterine Cancer

The purpose of this phase III clinical trial, is to evaluate the efficacy and safety of concomitant chemo-radiotherapy with Cisplatin vs Gemcitabine as the first line of treatment in patients with locally advanced cervical cancer, with comorbidities and preserved renal function.

Participants needed: 140
Trial details
Phase: Phase 3Age: 18+Biological sex: FemaleType: InterventionalSponsor: National Institute of CancerologíaUpdated: May 28, 2025Locations: 1
Eligibility criteria

Singed informed consent. [+22]

Patients with a second neoplasm. [+11]

Read more